That doesn't mean they are not taking into consideration it. A number of breakthrough therapy designations are already granted for psilocybin while in the treatment of resistant depression—that is certainly, depression that does not respond to not less than two differing kinds of antidepressants—plus a broader approval can be about the horizon.